May your drug price be evergreen.

The concern with repurposing and recycling of old drugs is the following: while many of the changes made to those old drugs may earn new patents and exclusivities, they may not be significant from a patient benefit or therapeutic point of view.

also in 2,774 other papers

This figure involved 19 different exclusivities, including well-known and highly significant ones, such as the orphan drug exclusivity and the pediatric exclusivity, but also lesser-known exclusivities, such as the GAIN (Generating Antibiotic Incentives Now) exclusivity. 117 Unlike the patent data, the exclusivity data contained no discernable trend over time, as the numbers in Table 4 demonstrate.

also in 132,142 other papers